الرئيسية › سرطان الثدي › كاليفورنيا › Los Angeles
التجارب السريرية لـ سرطان الثدي في Los Angeles، CA
73 دراسات لـ سرطان الثدي تبحث عن مشاركين في مواقع داخل وحول Los Angeles (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
جارٍ التسجيلالمرحلة 1/2
- Research Site, Los Angeles
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
جارٍ التسجيلالمرحلة 3
- Cedars-Sinai Medical Center, Los Angeles
A Study of PHST001 in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- USC Norris Comprehensive Cancer Center, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
جارٍ التسجيلالمرحلة 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
جارٍ التسجيلالمرحلة 3
- Los Angeles Cancer Network Good Samaritan, Los Angeles
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 2
- LA Cancer Network, Los Angeles
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of California Los Angeles, Los Angeles
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
جارٍ التسجيلالمرحلة 1/2
- Ellison Medical Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
- University of California Los Angeles, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
جارٍ التسجيلالمرحلة 1
- Research Site, Los Angeles
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
جارٍ التسجيلالمرحلة 3
- Los Angeles Hematology Oncology Medical Group ( Site 0026), Los Angeles
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
جارٍ التسجيلالمرحلة 2
- Los Angeles Cancer Network, Los Angeles
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
جارٍ التسجيلالمرحلة 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
جارٍ التسجيلالمرحلة 2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- University of California Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 3
- Ellison Medical Institute, Los Angeles
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
جارٍ التسجيلالمرحلة 3
- Cedar Sinai - Samuel Oschin Cancer Center, Los Angeles
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- University of California, Los Angeles (Specimen Analysis only), Los Angeles
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
جارٍ التسجيلالمرحلة 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- UCLA Health 200 Medical Plaza, Los Angeles
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
جارٍ التسجيلالمرحلة 1
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
جارٍ التسجيلالمرحلة 1
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- California Research Institute, Los Angeles
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- START Los Angeles, Los Angeles
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
جارٍ التسجيلالمرحلة 2
- Los Angeles Cancer Network, Los Angeles
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
جارٍ التسجيلالمرحلة 3
- Ellison Medical Institute, Los Angeles
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
جارٍ التسجيلالمرحلة 3
- Los Angeles Cancer Network, Los Angeles
- Cedars-Sinai Cancer at Cedars-Sinai Medical Facility, Los Angeles
- Los Angeles Cancer Network_Century City, Los Angeles
- و 3 أخرى
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of Southern California, Los Angeles
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
جارٍ التسجيلالمرحلة 3
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- و 2 أخرى
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- University of California LA, Los Angeles
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- START Los Angeles, Los Angeles
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
جارٍ التسجيلالمرحلة 2
- Univ. of California Los Angeles, Los Angeles
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 1
- University California, Los Angeles, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- The Angeles Clinic and Research Institute, Los Angeles
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
جارٍ التسجيلالمرحلة 2
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
جارٍ التسجيلالمرحلة 2/3
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
جارٍ التسجيلالمرحلة الأولى المبكرة
- Cedars-Sinai Medical Center, Los Angeles
E-Mindfulness Approaches for Living After Breast Cancer
جارٍ التسجيلالمرحلة 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- و 1 أخرى
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
جارٍ التسجيلالمرحلة 1/2
- University of California Los Angeles Medical Center, Los Angeles
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
جارٍ التسجيلالمرحلة 1
- University of California LA, Los Angeles
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- START Los Angeles, Los Angeles
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Ellison Clinic at Saint John's, Los Angeles
Brain Health in Breast Cancer Survivors
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- University of California at Los Angeles, Los Angeles
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 1/2
- START Los Angeles, Los Angeles
EXoPERT EMERALD Clinical Study
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- City of Hope Duarte Cancer Center, Los Angeles
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
جارٍ التسجيلالمرحلة 2
- GSK Investigational Site, Los Angeles
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
جارٍ التسجيلالمرحلة 3
- UCLA Hematology Oncology Santa Monica, Los Angeles
Core Biopsies for Establishing a Breast Tumor Tissue Repository
جارٍ التسجيلدراسة رصدية
- USC Norris Comprehensive Cancer Center, Los Angeles
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
جارٍ التسجيلالمرحلة 2
- University of Southern California, Los Angeles
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
جارٍ التسجيلالمرحلة 3
- Los Angeles Cancer Network - Good Samaritan, Los Angeles
- Los Angeles Hematology Oncology Medical Group, Los Angeles
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
جارٍ التسجيل
- University of California Los Angeles, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
جارٍ التسجيل
- Oncology Institute for Hope and Innovation, Los Angeles
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
جارٍ التسجيلالمرحلة 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- و 1 أخرى
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
جارٍ التسجيلالمرحلة 2
- Cedars-Sinai Medical Center, Los Angeles
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
جارٍ التسجيل
- Beckman Research Institute of the City of Hope, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- USC / Norris Comprehensive Cancer Center, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
جارٍ التسجيلدراسة رصدية
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
جارٍ التسجيلالمرحلة 1
- USC - Norris Comprehensive Cancer Center, Los Angeles
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
جارٍ التسجيلالمرحلة 1
- Los Angeles County-USC Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer
جارٍ التسجيل
- UCLA, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- University of Southern California, Los Angeles
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
جارٍ التسجيلالمرحلة 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
جارٍ التسجيلمرحباً بالمتطوعين الأصحاء
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
جارٍ التسجيلالمرحلة 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Cedars Sinai Medical Center, Los Angeles
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
جارٍ التسجيلالمرحلة 2
- Valkyrie Clinical Trials, Los Angeles
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
جارٍ التسجيلالمرحلة 1/2
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
جارٍ التسجيلدراسة رصديةمرحباً بالمتطوعين الأصحاء
- MiraKind, Los Angeles
تجارب سرطان الثدي في مدن أخرى
- New York City, NY136 دراسات
- Houston, TX126 دراسات
- Boston, MA112 دراسات
- Nashville, TN81 دراسات
- Edison, NJ68 دراسات
- St. Louis, MO64 دراسات
- Queens, NY64 دراسات
- Durham, NC64 دراسات
- Chicago, IL59 دراسات
- Philadelphia, PA56 دراسات
- Dallas, TX55 دراسات
- Arlington, VA47 دراسات
دراسات أخرى في Los Angeles
- سرطان الرئة غير صغير الخلايا87 دراسات
- السرطان (جميع الأنواع)74 دراسات
- سرطان البروستاتا61 دراسات
- سرطان القولون والمستقيم59 دراسات
- السرطان النقيلي57 دراسات
- سرطان المبيض50 دراسات
- سرطان الرئة45 دراسات
- سرطان الخلايا الحرشفية في الرأس والرقبة42 دراسات
- سرطان البنكرياس35 دراسات
- سرطان بطانة الرحم34 دراسات
- ميلانوما34 دراسات
- سرطان الثدي الثلاثي السلبي27 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.